Denali Therapeutics, Inc. (DNLI)
24.20
-0.72
(-2.89%)
USD |
NASDAQ |
Aug 24, 16:00
23.73
-0.47
(-1.94%)
After-Hours: 20:00
Denali Therapeutics Enterprise Value : 3.308B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 3.308B |
| August 20, 2026 | 3.313B |
| August 19, 2026 | 3.431B |
| August 18, 2026 | 3.211B |
| August 17, 2026 | 3.217B |
| August 14, 2026 | 3.225B |
| August 13, 2026 | 3.292B |
| August 12, 2026 | 3.364B |
| August 11, 2026 | 3.272B |
| August 10, 2026 | 3.321B |
| August 07, 2026 | 3.294B |
| August 06, 2026 | 3.278B |
| August 05, 2026 | 3.228B |
| August 04, 2026 | 3.189B |
| August 03, 2026 | 3.026B |
| July 31, 2026 | 3.005B |
| July 30, 2026 | 3.217B |
| July 29, 2026 | 3.137B |
| July 28, 2026 | 3.169B |
| July 27, 2026 | 3.093B |
| July 24, 2026 | 3.019B |
| July 23, 2026 | 3.069B |
| July 22, 2026 | 3.104B |
| July 21, 2026 | 3.134B |
| July 20, 2026 | 2.986B |
| Date | Value |
|---|---|
| July 17, 2026 | 3.048B |
| July 16, 2026 | 2.958B |
| July 15, 2026 | 3.005B |
| July 14, 2026 | 2.946B |
| July 13, 2026 | 3.558B |
| July 10, 2026 | 3.430B |
| July 09, 2026 | 3.674B |
| July 08, 2026 | 3.591B |
| July 07, 2026 | 3.530B |
| July 06, 2026 | 3.439B |
| July 02, 2026 | 3.454B |
| July 01, 2026 | 3.478B |
| June 30, 2026 | 3.436B |
| June 29, 2026 | 3.160B |
| June 26, 2026 | 3.109B |
| June 25, 2026 | 2.976B |
| June 24, 2026 | 2.990B |
| June 23, 2026 | 2.982B |
| June 22, 2026 | 2.868B |
| June 18, 2026 | 2.751B |
| June 17, 2026 | 2.779B |
| June 16, 2026 | 2.532B |
| June 15, 2026 | 2.578B |
| June 12, 2026 | 2.489B |
| June 11, 2026 | 2.387B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
| Biogen, Inc. | 39.09B |
| Oncolytics Biotech, Inc. | 101.41M |
| Sangamo Therapeutics, Inc. | 50.70M |
| Sarepta Therapeutics, Inc. | 2.242B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -127.55M |
| Revenue (Quarterly) | 3.604M |
| Total Expenses (Quarterly) | 131.16M |
| EPS Diluted (Quarterly) | -0.681 |
| Gross Profit Margin (Quarterly) | -52.39% |
| Profit Margin (Quarterly) | -3.54K% |
| Earnings Yield | -11.73% |
| Normalized Earnings Yield | -11.73 |